The safety and PK profile of seribantumab described here, combined with the demonstrated preclinical activity in tumor models with NRG1 fusions, support a tumor agnostic strategy for further development of seribantumab in patients with tumors driven by NRG1 fusions. Here, NRG1 is linked to neoplasm.